Continued Growth In Pharma R&D For 2025

The number of drugs in development continued to increase in 2024, though the rate of growth was slower than in 2023. Pfizer regained its top spot in terms of companies with drugs in development, while China continued to gain pipeline share at a faster pace than most other geographic areas. This infographic breaks down the key findings of Citeline's full Pharma R&D Annual Review 2025 through easy-to-understand graphs and charts that highlight trends in the R&D pipeline.